Skip to content

Study · Non-randomized trial · n = 140 · 2008

6 results

[Neuroimmunocorrection therapy for the prophylaxis of infectious complications in acute stroke patients].

Kul'chikov AE, Makarenko AN

Eksperimental'naia i klinicheskaia farmakologiia1 Nov 2008

PMID19140514 (opens in a new tab)PepBankPUB-19140514
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with severe acute ischemic stroke, cerebrolysin therapy decreased clinical pneumonia frequency compared with the control group.

    In plain wordsIn patients with severe stroke, cerebrolysin therapy reduced pneumonia frequency compared with the control group.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseClinical pneumonia frequency
    Study

    n = 140

    Comparator
    Control group
    Outcome group
    Infection and antimicrobial activity · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It is established that the proposed neuroimmunocorrection therapy with cerebrolysin decreases the frequency of the clinical pneumonia development.
    2 context sentences
    Summary · context
    Neuroimmunocorrection therapy with cerebrolysin has been used for the prophylaxis of clinical pneumonia development in the early stage of acute stroke in a group of 140 patients with heavy clinical course of acute ischemic stroke (AIS).
    Summary · context
    All patients in the test and control groups received the basal anti-AIS therapy and antibacterial drugs (IV-generation cephalosporins) in case of pneumonia development.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke patients, cerebrolysin decreased lethality compared with the control group.

    In plain wordsIn stroke patients, cerebrolysin reduced deaths compared with the control group.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseLethality
    Study

    n = 140

    Comparator
    Control group
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The use of cerebrolysin decreases lethality, normalizes the impaired immunity indices, accelerates the restoration of violated neural functions, suppresses pneumonia development, restores the level of albumin, and normalizes the laboratory indices of inflammatory syndrome.
    2 context sentences
    Summary · context
    Neuroimmunocorrection therapy with cerebrolysin has been used for the prophylaxis of clinical pneumonia development in the early stage of acute stroke in a group of 140 patients with heavy clinical course of acute ischemic stroke (AIS).
    Summary · context
    All patients in the test and control groups received the basal anti-AIS therapy and antibacterial drugs (IV-generation cephalosporins) in case of pneumonia development.
  3. 03HumanNon-randomized trialMechanism

    In acute ischemic stroke patients, cerebrolysin normalized impaired immunity indices.

    In plain wordsIn stroke patients, cerebrolysin normalized impaired immune measures.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableImpaired immunity indices
    Study

    n = 140

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The use of cerebrolysin decreases lethality, normalizes the impaired immunity indices, accelerates the restoration of violated neural functions, suppresses pneumonia development, restores the level of albumin, and normalizes the laboratory indices of inflammatory syndrome.
    2 context sentences
    Summary · context
    Neuroimmunocorrection therapy with cerebrolysin has been used for the prophylaxis of clinical pneumonia development in the early stage of acute stroke in a group of 140 patients with heavy clinical course of acute ischemic stroke (AIS).
    Summary · context
    All patients in the test and control groups received the basal anti-AIS therapy and antibacterial drugs (IV-generation cephalosporins) in case of pneumonia development.
  4. 04HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke patients, cerebrolysin accelerated restoration of impaired neural functions.

    In plain wordsIn stroke patients, cerebrolysin accelerated recovery of impaired neural functions.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNeural function restoration
    Study

    n = 140

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The use of cerebrolysin decreases lethality, normalizes the impaired immunity indices, accelerates the restoration of violated neural functions, suppresses pneumonia development, restores the level of albumin, and normalizes the laboratory indices of inflammatory syndrome.
    2 context sentences
    Summary · context
    Neuroimmunocorrection therapy with cerebrolysin has been used for the prophylaxis of clinical pneumonia development in the early stage of acute stroke in a group of 140 patients with heavy clinical course of acute ischemic stroke (AIS).
    Summary · context
    All patients in the test and control groups received the basal anti-AIS therapy and antibacterial drugs (IV-generation cephalosporins) in case of pneumonia development.
  5. 05HumanNon-randomized trialMechanism

    In acute ischemic stroke patients, cerebrolysin restored albumin levels.

    In plain wordsIn stroke patients, cerebrolysin restored albumin levels.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableAlbumin level
    Study

    n = 140

    Outcome group
    Protein and amino acid metabolism · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The use of cerebrolysin decreases lethality, normalizes the impaired immunity indices, accelerates the restoration of violated neural functions, suppresses pneumonia development, restores the level of albumin, and normalizes the laboratory indices of inflammatory syndrome.
    2 context sentences
    Summary · context
    Neuroimmunocorrection therapy with cerebrolysin has been used for the prophylaxis of clinical pneumonia development in the early stage of acute stroke in a group of 140 patients with heavy clinical course of acute ischemic stroke (AIS).
    Summary · context
    All patients in the test and control groups received the basal anti-AIS therapy and antibacterial drugs (IV-generation cephalosporins) in case of pneumonia development.
  6. 06HumanNon-randomized trialMechanism

    In acute ischemic stroke patients, cerebrolysin normalized laboratory indices of inflammatory syndrome.

    In plain wordsIn stroke patients, cerebrolysin normalized laboratory measures of inflammation.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableInflammatory syndrome laboratory indices
    Study

    n = 140

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The use of cerebrolysin decreases lethality, normalizes the impaired immunity indices, accelerates the restoration of violated neural functions, suppresses pneumonia development, restores the level of albumin, and normalizes the laboratory indices of inflammatory syndrome.
    2 context sentences
    Summary · context
    Neuroimmunocorrection therapy with cerebrolysin has been used for the prophylaxis of clinical pneumonia development in the early stage of acute stroke in a group of 140 patients with heavy clinical course of acute ischemic stroke (AIS).
    Summary · context
    All patients in the test and control groups received the basal anti-AIS therapy and antibacterial drugs (IV-generation cephalosporins) in case of pneumonia development.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.